Covaxin - Latest News, Analysis, Opinion

Economy

The COVID-19 Working Group (CWG), in its July 20 meeting, reviewed data of the double-blind randomized phase-3 clinical study which evaluated the immunogenicity and safety of booster dose of Corbevax vaccine when administered to COVID-19-negative adult volunteers of age 18-80 years previously vaccinated with two doses of either Covishield or Covaxin.

Covaxin Proven Safe For Children Of 2-18 Years Age Group In Phase III Study: Bharat Biotech

Bharat Biotech said in the study, no serious adverse event was reported. A total of 374 adverse events were reported, and the majority of adverse events were mild in nature and resolved within one day. Pain at the injection site was the most commonly reported adverse event

Covaxin Shows Robust Safety & Immunogenicity In Children 2-18 Years

Economy

Bharat Biotech International Limited (BBIL), a global developer of vaccines for infectious diseases, today announced that BBV152 (COVAXINÒ), its whole-virion inactivated COVID-19 vaccine candidate, has proven to be safe, well-tolerated, and highly immunogenic in paediatric subjects in phase II/III study.

Covaxin's Clinical Trials Can Resume In US As FDA Lifts Hold

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation's observations on Covaxin manufacturing plants in India

Covaxin Gets Emergency Use Authorisation For Children Aged 6-12: Sources

The development comes after the Subject Expert Committee (SEC) of the DCGI asked Bharat Biotech for additional data on Covaxin, for administering it to children aged between 2-12 years, sources said

Covaxin Booster Amplifies Protection Against Variants Of Concern: ICMR Study

As a part of the study the antibody responses in sera of 51 participants who received two doses of Covaxin collected six months post second dose and 28 days after receiving a third (booster) dose (given on day 215th post second dose) and its impact against the Omicron VoC was evaluated

Covishield And Covaxin Doses To Cost Rs 225 Now In Private Hospitals

The Serum Institute of India has cut the rates of Covishield from ₹600 to ₹225 per dose, while Bharat Biotech has brought down the price of Covaxin from ₹1,200 to ₹225

India's Expert Panel Advises Full Approval For Covishield, Covaxin

Healthcare Healthcare

Covaxin and Covishield received emergency use authorisation in India in January 2021, with more than a combined 1.5 billion doses having been administered so far, according to government data.

Govt Expert Panel Recommends Regular Market Approval For Covishield, Covaxin

Pharma companies Serum Institute of India (SII) and Bharat Biotech had submitted applications to the Drugs Controller General of India (DCGI) seeking regular market authorisation for their respective COVID-19 vaccines Covishield and Covaxin.

Covaxin Shows 50% Effectiveness Against Symptomatic COVID-19 In Real-World Assessment: Lancet Study

Companies & Markets

The COVID-19 vaccination centre at AIIMS New Delhi exclusively offered Covaxin beginning January 16 this year to all of its 23,000 employees.

Covaxin 77.8% Effective Against COVID-19: Lancet Study

The efficacy analysis demonstrated that Covaxin to be 93.4 per cent effective against severe symptomatic Covid-19.

WHO Approval To Covaxin Will Improve Ease Of Travel For Vaccinated Indians: MEA

MEA Spokesperson Arindam Bagchi said 96 countries have either accepted WHO-approved vaccines, which would include both Covishield and Covaxin, or in some cases only Covishield or Covaxin.

UK To Add India's Covaxin To Approved Vaccine List For Inbound Travellers

Healthcare Pharma

The move follows the World Health Organisation's (WHO) Emergency Use Listing for Covaxin, which is the second most used formulation in India.

Bharat Biotech's Partner Ocugen Files EUA Request With FDA For Paediatric Use Of Covaxin